Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
A total of 10 new medicines will join Japan’s NHI reimbursement price list on August 13, led by a subcutaneous formulation of Sanofi’s multiple myeloma therapy Sarclisa (isatuximab), which carries the largest peak sales outlook on the roster. The Central…
To read the full story
Related Article
- Sanofi’s ITP Drug Wayrilz Goes on Sale in Japan
October 21, 2026
- Sarclisa SC Can Meet Patient, Healthcare Worker Needs: Specialist
September 1, 2026
- Sanofi Debuts Sarclisa SC, Cutting Dosing Time
August 28, 2026
- Sobi’s Still’s Disease Drug Kineret Now Available in Japan
August 24, 2026
- Santen Releases Glaucoma Drug Rhopressa in Japan
August 18, 2026
- Organon Dysmenorrhea Drug Mercilon Set for Sept. 1 Launch
August 18, 2026
- Japan Approves Wegovy MASH Use, AstraZeneca’s Etcamah, Others
June 22, 2026
- Japan OKs Bayer’s MRI Agent, Haihe’s PI3Kα Med, Enhertu’s Tumor-Agnostic Use, and More
March 24, 2026
REGULATORY
- MOF Panel Pushes for Full Drug Price Revision in FY2027: Budget Proposal
November 20, 2026
- Mumps Shots Gain Strong Backing as Japan Weighs FY2027 NIP Priorities
November 20, 2026
- Lilly’s Oral GLP-1 Obesity Drug Heads to Dec. 2 Panel Review, Eyes Japan First
November 19, 2026
- Pharma Prods LDP to Rethink CEA Expansion, Project Team to Compile Proposal
November 19, 2026
- First Pralia Biosimilars Inching Closer to Japan Approval, 5 Products Lined Up
November 19, 2026





